Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jun 06, 2014 1:10pm
145 Views
Post# 22637903

RE:RE:RE:RE:RE:RE:RE:RE:RE:A few thoughts

RE:RE:RE:RE:RE:RE:RE:RE:RE:A few thoughtsHi narmac.

I agree in the sense that Zenith has no value to me because it lacks liquidity. I've asked Zenith twice about when they are going to create liquidity either in the form of IPOs or creating an internal market and their answers were non-commital...dissappointing.

However, there are BPs and pharma based venture capital companies out there that see the future of epigenetics and the reported results achieved by Zenith. They will be putting a value on it just like large software companies valuing new apps that have never made a buck.

From a Zenith POV they know the market potential with each of their platforms and thus can establish some very crude sense of potential value. They better be doing this because without it they have no negotiating platform. They can and should be looking at other related IPOs and CVRs as well to establish a perspective on value.

At the end of the day the share price will be established by the market if they go public or by a private buyer.

Yes, it's current value is $0 (P/E ratio is infinite) on the books.

What does concern me is what Sanfran has pointed out with insiders bringing in funding at $1.00/share. Of course the funding is needed to keep these businesses moving and so they have the edge but I think they are getting share on the cheap. The current stock price is not reflective of the huge potential (that is if there is any probability of RVX being successful).

My birthday is on July 1st. I can tell you I was not smiling at my 2013 birthday (although I can only blame myself) BUT I do hope I'll be smiling this year. So fair I have hope but big doubts.

Cheers
Toinv
Bullboard Posts